Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call

Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.

Related Keywords

Canada , Japan , China , United States , Texas , Chinese , America , American , Bob Duggan , Allen Yang , Brad Canino , Bradley Canino , Manmeet Soni , Mostafa Ronaghi , Carter Gould , Dave Gancarz , Maky Zanganeh , Us National Cancer Institute , European Organization For Research , Summit Therapeutics Inc , Barclays , Team Summit , Nasdaq , American Association Of Cancer Research , American Society Of Clinical Oncology , Society For Immunotherapy Of Cancer , Summit Therapeutics , Call Transcript May , Summit Therapeutics First Quarter , Chief Business , Chief Executive Officer , Chief Operating Officer , Chief Financial Officer , Chief Medical , American Society , Clinical Oncology , European Lung Cancer Conference , European Organization , Cancer Institute , American Association , Cancer Research , Targeted Therapies , Lung Cancer , Chief Technology Officer , North America , Akeso Phase , Buying These , Gas Stocks , Reddit Stocks ,